男性乳腺癌治疗的真实世界证据荟萃分析
结果显示保乳手术与乳房切除术总生存无差异,胸壁放疗和他莫昔芬治疗均显著改善总生存,前哨淋巴结活检识别率和假阴性率与女性乳腺癌相当。
要点
- 保乳手术与乳房切除术的总生存无显著差异,保乳手术可有效且安全。
- 乳房切除术后胸壁放疗显著提高总生存(HR 0.67,95%CI 0.54–0.84)。
- 他莫昔芬治疗显著提高总生存(HR 0.62,95%CI 0.41–0.95),前哨淋巴结活检识别率97.4%、假阴性率7.4%。
核心结论
- 前哨淋巴结活检的识别率和假阴性率与女性乳腺癌相当。
- 保乳手术可有效且安全;乳房切除术后胸壁放疗和5年他莫昔芬治疗改善生存。
研究设计与样本
- 纳入研究评估保乳手术与乳房切除术、乳房切除术后放疗与否、前哨淋巴结活检准确性及多种内分泌治疗比较。
主要发现
- 保乳手术与乳房切除术的总生存汇总估计无差异。
- 乳房切除术后胸壁放疗较未放疗显著增加总生存(HR 0.67,95%CI 0.54–0.84)。
- 前哨淋巴结活检识别率汇总估计为97.4%,假阴性率为7.4%。
- 他莫昔芬治疗较未服用他莫昔芬显著增加总生存(HR 0.62,95%CI 0.41–0.95)。
临床怎么用
- 男性乳腺癌可考虑保乳手术,其总生存与乳房切除术无差异。
- 乳房切除术后可考虑胸壁放疗以改善总生存。
- 可考虑他莫昔芬治疗以改善总生存。
- 前哨淋巴结活检在男性乳腺癌中具有与女性乳腺癌相当的识别率和假阴性率。
局限性
- 男性乳腺癌临床试验罕见,本分析基于真实世界证据的合成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer is rare in men and managed by extrapolating from breast cancer in women. The clinicopathological features of male breast cancer, however, differ from those of female breast cancer. Because clinical trials are rare, the synthesis of real-world data is one method of integrating sufficient evidence on the optimal treatment for this patient population. METHODS: PubMed, Embase, and Cochrane Library databases were searched. Clinical studies were included if they evaluated the treatments of interest in male breast cancer; these evaluations included breast-conserving surgery (BCS) versus mastectomy, postmastectomy radiation therapy versus no radiation, the accuracy of sentinel lymph node biopsy (SLNB), and a comparison of various endocrine therapies. RESULTS: Forty studies were retrieved. The pooled estimate of overall survival (OS) revealed no difference between BCS and mastectomy groups. Postmastectomy radiation to the chest wall significantly increased OS relative to no postmastectomy radiation (hazard ratio (HR) 0.67, 95 per cent confidence interval 0.54 to 0.84). The pooled estimates of identification and false-negative rates of SLNB were 97.4 and 7.4 per cent respectively. Tamoxifen treatment was associated with significantly increased OS compared with no tamoxifen intake (HR 0.62, 0.41 to 0.95). CONCLUSION: Identification and false-negative rates for SLNB were comparable to those in female breast cancer. Breast-conserving surgery can be effective and safe; postmastectomy radiation to the chest wall and 5-year tamoxifen treatment improves survival.
引用
- Lin AP, Huang TW, Tam KW, et al. Treatment of male breast cancer: meta-analysis of real-world evidence. Br J Surg. 2021. PMID: 34476472. doi:10.1093/bjs/znab279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。